Market closed

Allakos/ALLK

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Allakos

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.

Ticker

ALLK
Trading on

Industry

Biotechnology

Employees

131

Allakos Metrics

BasicAdvanced
$61M
Market cap
-
P/E ratio
-$2.35
EPS
0.86
Beta
-
Dividend rate
$61M
0.86
$3.41
$0.54
367K
3.565
3.431
43.547
47.303
-49.29%
-121.54%
0.73
0.73
-0.587
22.28%
-15.15%

What the Analysts think about Allakos

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Allakos stock.

Allakos Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Allakos Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy ALLK

$

Sign up or log in to buy
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Allakos stock?

Allakos (ALLK) has a market cap of $61M as of October 06, 2024.

What is the P/E ratio for Allakos stock?

The price to earnings (P/E) ratio for Allakos (ALLK) stock is 0 as of October 06, 2024.

Does Allakos stock pay dividends?

No, Allakos (ALLK) stock does not pay dividends to its shareholders as of October 06, 2024.

When is the next Allakos dividend payment date?

Allakos (ALLK) stock does not pay dividends to its shareholders.

What is the beta indicator for Allakos?

Allakos (ALLK) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.